NCT05397379 - A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of HEC96719 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2021

Primary Completion Date

September 5, 2023

Study Completion Date

September 5, 2023

Conditions

Non-Alcoholic Steatohepatitis

Interventions

DRUG

HEC96719

Oral tablets

DRUG

Placebo

Comparator

Trial Locations (9)

NanFang Hospital of Southern Medical University, Guangzhou

Peking University People's Hospital, Beijing

Affiliated Hospitol of Guangdong Medical University, Guangzhou

Union Hospital, TongJi Medical College, HuaZhong University of Science and Technology, Wuhan

Hunan Provincial People's Hospital, Changsha

The First Hospital of Jilin University, Changchun

The First Affiliated Hospitol of Xi'an Jiaotong University, Xi’an

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The First Affiliated Hospitol of Wenzhou Medical University, Wenzhou

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY